- Janus Kinase Inhibitors in the Treatment of Alopecia Areata2023 | Third Faculty of Medicine
- Efficacy of Janus kinase inhibitors on skin syndrome in patients with psoritic arthritis2022 | First Faculty of Medicine
- Clinical experience with Janus kinase inhibitors2019 | First Faculty of Medicine
- Janus kinase inhibitors in the treatment of rheumatoid arthritis2020 | First Faculty of Medicine
- The role od Janus kinase inhibitors in the therapy of psoriatic arthritis2023 | First Faculty of Medicine
- Janus kinase inhibitors in clinical practice: data from the ATTRA registry2020 | First Faculty of Medicine
- Expanding possibilities of rheumatoid arthritis and spondyloarthritis treatment2018 | Faculty of Medicine in Hradec Králové
- Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation2018 | First Faculty of Medicine, Second Faculty of Medicine
- Tofacitinib in treating psoriatic arthritis2019 | First Faculty of Medicine
- Possibilities for monotherapy with tofacitinib in clinical practice2018 | First Faculty of Medicine
- ASAS‑EULAR recommendations for the treatment of axial spondylarthritis: an update2023 | First Faculty of Medicine
- Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe2023 | First Faculty of Medicine
- Selected case reports from the tofacitinib clinical program2019 | First Faculty of Medicine
- New guidelines for treatment of rheumatoid arthritis2018 | First Faculty of Medicine
- ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update2023 | First Faculty of Medicine
- Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years2024 | First Faculty of Medicine
- Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice2020 | First Faculty of Medicine